![Clinical development of targeted and immune based anti-cancer therapies | Journal of Experimental & Clinical Cancer Research | Full Text Clinical development of targeted and immune based anti-cancer therapies | Journal of Experimental & Clinical Cancer Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13046-019-1094-2/MediaObjects/13046_2019_1094_Fig1_HTML.png)
Clinical development of targeted and immune based anti-cancer therapies | Journal of Experimental & Clinical Cancer Research | Full Text
![Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations | Journal of Experimental & Clinical Cancer Research | Full Text Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations | Journal of Experimental & Clinical Cancer Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13046-021-02111-5/MediaObjects/13046_2021_2111_Fig2_HTML.png)
Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations | Journal of Experimental & Clinical Cancer Research | Full Text
![Small molecules in targeted cancer therapy: advances, challenges, and future perspectives | Signal Transduction and Targeted Therapy Small molecules in targeted cancer therapy: advances, challenges, and future perspectives | Signal Transduction and Targeted Therapy](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41392-021-00572-w/MediaObjects/41392_2021_572_Fig8_HTML.png)
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives | Signal Transduction and Targeted Therapy
![Overcoming cancer therapeutic bottleneck by drug repurposing | Signal Transduction and Targeted Therapy Overcoming cancer therapeutic bottleneck by drug repurposing | Signal Transduction and Targeted Therapy](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41392-020-00213-8/MediaObjects/41392_2020_213_Fig6_HTML.png)
Overcoming cancer therapeutic bottleneck by drug repurposing | Signal Transduction and Targeted Therapy
![Do patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS Cancer Drugs Fund - Annals of Oncology Do patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS Cancer Drugs Fund - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/2fae9503-3933-4502-a08c-d056ac5e5fd5/gr1.jpg)
Do patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS Cancer Drugs Fund - Annals of Oncology
![Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations | Journal of Experimental & Clinical Cancer Research | Full Text Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations | Journal of Experimental & Clinical Cancer Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13046-021-02111-5/MediaObjects/13046_2021_2111_Fig3_HTML.png)
Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations | Journal of Experimental & Clinical Cancer Research | Full Text
![Overcoming cancer therapeutic bottleneck by drug repurposing | Signal Transduction and Targeted Therapy Overcoming cancer therapeutic bottleneck by drug repurposing | Signal Transduction and Targeted Therapy](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41392-020-00213-8/MediaObjects/41392_2020_213_Fig2_HTML.png)
Overcoming cancer therapeutic bottleneck by drug repurposing | Signal Transduction and Targeted Therapy
![Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis - The Lancet Oncology Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/ffad31b7-2bc1-48a7-ad16-3ee301730f72/gr1_lrg.jpg)
Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis - The Lancet Oncology
![Clinical development of targeted and immune based anti-cancer therapies | Journal of Experimental & Clinical Cancer Research | Full Text Clinical development of targeted and immune based anti-cancer therapies | Journal of Experimental & Clinical Cancer Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13046-019-1094-2/MediaObjects/13046_2019_1094_Fig2_HTML.png)
Clinical development of targeted and immune based anti-cancer therapies | Journal of Experimental & Clinical Cancer Research | Full Text
![Changes in clinical trials of cancer drugs in mainland China over the decade 2009–18: a systematic review - The Lancet Oncology Changes in clinical trials of cancer drugs in mainland China over the decade 2009–18: a systematic review - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/3177a3f3-5388-4df0-b83b-b35e6ecf71a3/gr1_lrg.gif)
Changes in clinical trials of cancer drugs in mainland China over the decade 2009–18: a systematic review - The Lancet Oncology
![Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine - ScienceDirect Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0753332220302006-ga1.jpg)